11.08
+0.69(+6.64%)
Currency In USD
| Previous Close | 10.39 |
| Open | 10.29 |
| Day High | 11.2 |
| Day Low | 10.29 |
| 52-Week High | 26.5 |
| 52-Week Low | 8.46 |
| Volume | 28,917 |
| Average Volume | 90,036 |
| Market Cap | 287.57M |
| PE | 2.08 |
| EPS | 5.33 |
| Moving Average 50 Days | 10.5 |
| Moving Average 200 Days | 16.28 |
| Change | 0.69 |
If you invested $1000 in Cartesian Therapeutics, Inc. (RNAC) since IPO date, it would be worth $26.38 as of July 01, 2025 at a share price of $11.08. Whereas If you bought $1000 worth of Cartesian Therapeutics, Inc. (RNAC) shares 5 years ago, it would be worth $130.05 as of July 01, 2025 at a share price of $11.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
GlobeNewswire Inc.
May 30, 2025 11:00 AM GMT
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first part
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
GlobeNewswire Inc.
May 13, 2025 11:00 AM GMT
FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to par
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
GlobeNewswire Inc.
Apr 08, 2025 11:00 AM GMT
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observe